Department of Musculoskeletal Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy.
Department of Musculoskeletal Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy.
Orthop Traumatol Surg Res. 2018 Jun;104(4):533-538. doi: 10.1016/j.otsr.2018.03.009. Epub 2018 Apr 11.
The humerus is the second most common long bone site of metastatic disease from renal cell carcinomas (RCC) after femur. Surgery has an important role in the treatment of these lesions due to renal cell tumor's resistance to chemotherapy and radiotherapy.
Prosthetic replacement is an effective and safe solution in treatment of renal humeral metastasis.
Fifty-six patients affected by RCC bone metastases of the humerus that underwent a surgical reconstruction were rewised. Thirty-five lesions were localized on proximal third, 12 on the shaft, 9 on distal third. Among proximal 29 were treated with resection and endoprosthetic replacement and 6 with plate and cement. Six diaphyseal lesions were stabilized with intramedullary nailing, 5 with plate and cement and 1 with an intercalary prosthesis. Regarding distal lesions, 7 elbow prostheses and 2 plates and cement were used.
The average age was 63years. Metastasis was single in 55% of cases, and in 45% metachronous. A pathologic fracture (PF) occurred in 64% of cases. Only 9% of patients had a mechanical complication, 7% an infection and 5% neurological deficit. A local recurrence occurred in 14% of patients. An implant failure has been observed in 10 patients, 5 for mechanical complications, 2 for infections and 3 for local recurrence; of these 7 were treated with a prosthesis and 3 with plate and cement. The mean value of MSTS score was 64%, 63% and 59% respectively in patients with proximal, diaphyseal and distal humerus metastases.
Solitary and metachronous bone metastases have a longer survival. Disease-free interval>2years is another important prognostic factor. Reconstruction with a modular prosthesis is recommended in proximal and distal third. Instead in diaphyseal lesions a closed reduction and fixation with intramedullary locked nailing are preferred. When surgical indications are correctly followed, good oncologic and functional outcomes are obtained, leading to markedly improvement of patients' quality of life.
Level of evidence: IV.
肱骨是继股骨之后肾癌(RCC)转移的第二常见长骨部位。由于肾细胞肿瘤对化疗和放疗有抵抗力,手术在治疗这些病变中起着重要作用。
假体置换是治疗肾肱骨转移的有效且安全的解决方案。
对 56 名接受手术重建的 RCC 肱骨转移患者进行了回顾性研究。35 处病变位于近端三分之一,12 处位于骨干,9 处位于远端三分之一。其中近端 29 处采用切除和内置假体置换治疗,6 处采用钢板和水泥固定。6 处骨干病变采用髓内钉固定,5 处采用钢板和水泥固定,1 处采用间插假体。对于远端病变,使用了 7 个肘部假体和 2 个钢板和水泥。
平均年龄为 63 岁。55%的病例为单发转移,45%为多发转移。64%的病例发生病理性骨折(PF)。只有 9%的患者发生机械并发症,7%的患者发生感染,5%的患者发生神经缺损。14%的患者出现局部复发。10 例患者出现植入物失败,5 例因机械并发症,2 例因感染,3 例因局部复发;其中 7 例采用假体治疗,3 例采用钢板和水泥固定。肱骨近端、骨干和远端转移患者的 MSTS 评分平均值分别为 64%、63%和 59%。
单发和多发骨转移患者的生存期较长。无疾病间隔>2 年是另一个重要的预后因素。建议在近端和远端三分之一处采用模块化假体重建。相反,骨干病变采用闭合复位和带锁髓内钉固定。当正确遵循手术适应证时,可获得良好的肿瘤学和功能结果,显著提高患者的生活质量。
证据水平:IV。